Form 4: Cumberland Pharmaceuticals Director James Jones Acquires 1,000 Shares

Director James Jones of Cumberland Pharmaceuticals acquired 1,000 shares of common stock at $5.17 per share on March 17, 2025.

Summary

• On March 17, 2025, James Jones, a director of Cumberland Pharmaceuticals, acquired 1,000 shares of the company's common stock.
• The shares were purchased at a price of $5.17 per share.
• Following the transaction, Jones directly owns 42,646 shares of Cumberland Pharmaceuticals.
• The acquisition was made via a restricted stock award that will vest 100% on March 17, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director's stock purchase. While insider buying can be seen as a positive signal, it's a relatively small transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Key Dates